What is mTOR?
mTOR (mechanistic target of rapamycin) is a serine/threonine kinase that integrates growth-factor, nutrient, and energy signals to control protein synthesis, autophagy, and cell growth. Sits downstream of Akt in the PI3K-Akt-mTOR cascade.
What the research literature says
mTOR exists in two functionally distinct complexes: mTOR complex 1 (mTORC1, rapamycin-sensitive) and mTOR complex 2 (mTORC2, less rapamycin-sensitive). mTORC1 integrates inputs from growth-factor signalling (via Akt-mediated inhibition of the TSC1/TSC2 complex), nutrient availability (via amino-acid-sensing complexes), and energy status (via AMPK) to control cap-dependent protein synthesis and to suppress autophagy.
mTORC2 sits upstream of Akt rather than downstream — its phosphorylation of Akt on Ser473 is one of the two activating modifications required for full Akt activity. The reciprocal positioning means PI3K-Akt-mTOR signalling forms an interconnected network rather than a strictly linear cascade. The Hsieh BPC-157 work documented Akt phosphorylation downstream of VEGFR2 (PMID 27847966), with mTOR-axis engagement as an implicit downstream consequence consolidated across the Sikiric 2024 review (PMID 38980576).
The detailed coverage of mTOR’s role in peptide-research signalling is in the mTOR glossary entry.
Why this matters in research context
mTOR matters in peptide-research contexts as the downstream signalling node where receptor engagement (via PI3K-Akt) translates into protein-synthesis and cell-growth pharmacology. Researchers studying anabolic or growth-regulatory pharmacology of catalog peptides should account for mTOR-axis engagement as the downstream consequence of upstream receptor activation. mTORC1 activity is measured by Western blot for phospho-S6K1 (Thr389) and phospho-4E-BP1 (Thr37/46) as the canonical downstream readouts. Pharmacological mTORC1 inhibition with rapamycin or the ATP-competitive mTOR inhibitors is the standard tool for confirming pathway involvement in cell-culture and animal-model research designs.
Related compounds
- BPC-157 10mg — VEGFR2-Akt-mTOR cascade
- MOTS-c 10mg — AMPK-mTOR cross-regulation
- mTOR (glossary entry) — detailed mechanism reference
Related research questions
References
- Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl) 2017;95(3):323-333. [PMID 27847966]
- Sikiric P et al. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. Inflammopharmacology 2024;32(5):3119-3161. [PMID 38980576]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.